N/A
Completed N=392
GANfort® in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Are Insufficiently Responsive to Monotherapy
Glaucoma, Open-Angle · Hypertension
Source: ClinicalTrials.gov NCT01628601 ↗
Enrolled (actual)
392
Serious AEs
0.3%
Results posted
Sep 2012
Primary outcomePrimary: Change From Baseline in Intraocular Pressure (IOP) — 22.0; -6.0; 22.0; -6.0 Millimeters of Mercury (mmHg)
Summary
This is an observational study of patients diagnosed with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) who are insufficiently responsive to monotherapy and who are prescribed GANfort® (fixed combination of 0.3 mg bimatoprost and 5 mg timolol) by their physician.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in Intraocular Pressure (IOP) |
22.0; -6.0; 22.0; -6.0 | — |
| SECONDARY Physician Assessment of Tolerability Using a 4-Point Scale |
340 | — |
| SECONDARY Patient Assessment of Tolerability Using a 4-Point Scale |
319 | — |
| SECONDARY Physician Assessment of Adherence to GANfort® |
112 | — |
| SECONDARY Patients Continuing With GANfort® After 18 Weeks |
329 | — |
Eligibility Criteria
Inclusion Criteria
- Diagnosis of primary open angle glaucoma or ocular hypertension
- Prescribed GANfort® (fixed combination 0.3 mg bimatoprost and 5 mg timolol)
Exclusion Criteria
- None
Data sourced from ClinicalTrials.gov (NCT01628601). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.